Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

Charles J. Love, Jr. appealed a decision regarding the reduction of his disability rating for service-connected prostate cancer. Initially rated at 100% due to active cancer, his rating was reduced to 20% after his cancer went into remission. Love argued that the procedural protections of 38 C.F.R. § 3.344, which require certain steps before reducing long-standing disability ratings, should apply to his case.The Veterans Benefits Administration Regional Office (RO) proposed the reduction in February 2019, which was finalized in September 2019. Love appealed to the Board of Veterans’ Appeals, which upheld the RO’s decision. He then appealed to the Court of Appeals for Veterans Claims, arguing that the reduction was improper without following § 3.344. The Veterans Court, referencing its decision in Foster v. McDonough, ruled that the procedural protections of § 3.344 did not apply to disabilities rated under diagnostic code 7528 for prostate cancer, as the diagnostic code itself provided specific procedures for rating changes.The United States Court of Appeals for the Federal Circuit reviewed the case. The court agreed with the Veterans Court, holding that the specific procedures outlined in diagnostic code 7528 for prostate cancer, which include a mandatory VA examination six months after treatment cessation, supersede the general procedural protections of § 3.344. The court found that applying § 3.344 would create conflicting standards and redundancy. Therefore, the reduction of Love’s rating was affirmed as proper under the specific guidelines of diagnostic code 7528. The court affirmed the decision of the Veterans Court, concluding that the procedural protections of § 3.344 do not apply to diagnostic code 7528. View "Love v. McDonough" on Justia Law

International Development Solutions, LLC (IDS), a security service contractor, entered into a contract with the Department of State for the provision of personal protection services in Afghanistan. IDS was initially a joint venture between ACADEMI Training Center, Inc. (ATCI) and Kaseman, LLC. However, ATCI later purchased all of Kaseman, LLC’s membership interest in IDS, making IDS a sole member LLC with ATCI as the sole member and owner. IDS then sold and transferred all of its interests in all of its contracts, subcontracts, and all property and assets to ATCI. ATCI requested the State to recognize it as the successor-in-interest to IDS’s contract through a formal novation agreement, but the State denied the request.The Civilian Board of Contract Appeals denied IDS’s consolidated appeal seeking cost-reimbursement of tax payments made by related corporate entities. The Board found no entitlement to reimbursement as IDS did not present evidence that tax amounts paid were costs incurred by IDS, the contractor, rather than by entities higher in IDS’s ownership chain.The United States Court of Appeals for the Federal Circuit affirmed the Board’s decision. The court found substantial evidence supporting the Board’s finding that IDS did not present evidence that tax amounts paid were costs incurred by IDS, the contractor, rather than by entities higher in IDS’s ownership chain. Therefore, IDS was not entitled to reimbursement. View "INTERNATIONAL DEVELOPMENT SOLUTIONS, LLC v. SECRETARY OF STATE " on Justia Law

The case involves Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited, and Mochida Pharmaceutical Co., Ltd. (collectively, “Amarin”) and Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals PLC (collectively, “Hikma”). Amarin markets and sells icosapent ethyl, an ethyl ester of an omega-3 fatty acid commonly found in fish oils, under the brand name Vascepa®. In 2012, the U.S. Food and Drug Administration (“FDA”) approved Vascepa for the treatment of severe hypertriglyceridemia. In 2019, following additional research and clinical trials, the FDA approved Vascepa for a second use: as a treatment to reduce cardiovascular risk in patients having blood triglyceride levels of at least 150 mg/dL.In the United States District Court for the District of Delaware, Hikma moved to dismiss Amarin’s complaint for failure to state a claim. The court granted Hikma’s motion, concluding that Amarin’s allegations against Hikma did not plausibly state a claim for induced infringement.The United States Court of Appeals for the Federal Circuit reversed the decision of the district court. The court held that Amarin had plausibly pleaded that Hikma had induced infringement of the asserted patents. The court noted that the case was not a traditional Hatch-Waxman case or a section viii case, but rather a run-of-the-mill induced infringement case arising under 35 U.S.C. § 271(b). The court concluded that the totality of the allegations, taken as true, plausibly plead that Hikma “actively” induced healthcare providers’ direct infringement. View "AMARIN PHARMA, INC. v. HIKMA PHARMACEUTICALS USA INC. " on Justia Law

The case revolves around Ravi Teja, an Indian citizen, who paid thousands of dollars to enroll at the "University of Farmington," expecting to take classes. Unbeknownst to him, the University was a fictitious entity created by the Department of Homeland Security (DHS) as part of an undercover operation to target fraud involving student visas. When the operation came to light, the government neither provided the education Ravi had paid for nor refunded his money. Ravi filed a lawsuit against the United States in the United States Court of Federal Claims, alleging a breach of contract and an accompanying breach of the implied covenant of good faith and fair dealing.The United States Court of Federal Claims dismissed Ravi's complaint for lack of subject-matter jurisdiction, without addressing other issues. The court reasoned that its jurisdiction under the Tucker Act does not extend to contracts entered into by the government when acting as a sovereign unless those contracts unmistakably subject the government to damages in the event of breach. The court concluded that the government was acting in its sovereign capacity as it entered into the alleged contract in furtherance of an undercover law-enforcement operation, and that the alleged contract did not unmistakably subject the government to damages in the event of breach.On appeal, the United States Court of Appeals for the Federal Circuit reversed the Claims Court’s dismissal and remanded the case for further proceedings. The Appeals Court concluded that the Claims Court had jurisdiction pursuant to the Tucker Act over the agreement alleged by Ravi. The court disagreed with the Claims Court's interpretation of the Tucker Act, stating that the contract in question did not concern what was promised to happen or not to happen in a different proceeding in another adjudicatory forum, and thus did not fall into the narrow exception carved out by precedent. The court remanded the case for further proceedings, noting that other grounds not reached by the Claims Court but raised by the government as alternative bases to affirm warranted further exploration. View "RAVI v. US " on Justia Law

The case involves Hahnenkamm, LLC and the United States Forest Service. Hahnenkamm sold a parcel of land to the Forest Service. The purchase price was based on an appraisal that was supposed to comply with the Uniform Appraisal Standards for Federal Land Acquisitions, also known as the Yellow Book. Hahnenkamm later sued the Forest Service, claiming that the appraisal did not comply with the Yellow Book and was not independent, thus breaching the purchase agreement.The United States Court of Federal Claims found in favor of Hahnenkamm, ruling that the Forest Service had breached the agreement by not supporting the purchase price with an independent, Yellow Book-compliant appraisal. The court rejected the government's defenses of waiver and equitable estoppel and awarded damages to Hahnenkamm.The United States Court of Appeals for the Federal Circuit partially reversed the lower court's decision. The appellate court found that Hahnenkamm could not have reasonably relied on the contractual representation that the appraisal was independent. However, the court remanded the case back to the lower court for further proceedings to determine whether Hahnenkamm reasonably relied on the representation that the appraisal was Yellow Book-compliant. The court also remanded the lower court's rejection of the equitable estoppel defense.On cross-appeal, Hahnenkamm argued that the lower court erred in its damages determination. The appellate court affirmed the lower court's damages determination, finding no abuse of discretion in its analysis. View "HAHNENKAMM, LLC v. US " on Justia Law

The case involves an appeal by Marmen Inc., Marmen Énergie Inc., Marmen Energy Co., the Government of Québec, and the Government of Canada against a decision by the U.S. Department of Commerce. The Department of Commerce had imposed countervailing duties on imports of certain utility scale wind towers from Canada, arguing that the Canadian government had provided illegal subsidies to the producers and exporters of these towers.The case was initially reviewed by the United States Court of International Trade, which upheld the Department of Commerce's decision. The appellants then appealed to the United States Court of Appeals for the Federal Circuit.The appellants argued that the Department of Commerce had erred in its assessment of three government programs and its computation of the sales denominator used to calculate the subsidy rate. They contended that the subsidy rate should have been de minimis, meaning it was too trivial or minor to merit consideration.The Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. Court of International Trade, ruling that the Department of Commerce's determination was supported by substantial evidence and was in accordance with the law. The court rejected the appellants' arguments, finding that the Department of Commerce had reasonably determined that the auditor's adjustment was unreliable, and that the three subsidy programs at issue did provide countervailable subsidies. View "GOVERNMENT OF QUEBEC v. US " on Justia Law

The case involves Beteiro, LLC, which owns several patents related to facilitating gaming or gambling activities at a remote location. The patents disclose an invention that allows a user to participate in live gaming or gambling activity via a user communication device, even if the user is not in the same location as the gaming venue. Beteiro filed multiple patent infringement cases against various companies, alleging that they infringe certain claims of the patents by providing gambling and event wagering services.The United States District Court for the District of New Jersey dismissed Beteiro's cases for failure to state a claim based on the subject matter ineligibility of the patent claims. The court found that the claims were directed to an abstract idea and did not contain an inventive concept. Beteiro appealed the decision.The United States Court of Appeals for the Federal Circuit affirmed the district court's decision. The court agreed that Beteiro's claims were directed to the abstract idea of exchanging information concerning a bet and allowing or disallowing the bet based on where the user is located. The court also found that the claims did not provide an inventive concept because they achieved the abstract steps using several generic computers. The court concluded that Beteiro's claims amounted to nothing more than the practice of an abstract idea using conventional computer equipment, including GPS on a mobile phone, which are not eligible for patent under current Section 101 jurisprudence. View "BETEIRO, LLC v. DRAFTKINGS INC. " on Justia Law

The case involves Dr. Deborah A. Perlick, who was employed by the Department of Veterans Affairs (VA) as a Research Health Science Specialist. During her tenure, she discovered approximately $78,000 missing from a study's funding and reported this to VA officials. Subsequently, she was terminated from her position. Perlick filed a complaint under the Whistleblower Protection Act (WPA), and the Merit Systems Protection Board (the Board) granted her request for corrective action, awarding her back pay through March 31, 2020. However, Perlick also sought consequential and compensatory damages, including future lost earnings, which the Board denied.The Board found that Perlick had established her claim of protected whistleblowing disclosures. However, it denied her request for consequential damages, stating that such damages are limited to out-of-pocket costs and do not include non-pecuniary damages. The Board also denied Perlick's request for future lost earnings, arguing that she had no guarantees of future employment beyond the completion date of her final project with the VA.The United States Court of Appeals for the Federal Circuit vacated the Board's decision and remanded the case for further proceedings. The court held that future lost earnings are recoverable as compensatory damages under the Whistleblower Protection Enhancement Act of 2012. The court found that the Board erred by improperly raising the burden for Perlick to establish these damages, requiring her to "guarantee" future employment to recover future lost earnings. The court instructed the Board to determine under the preponderance of the evidence standard whether Perlick met her burden to prove entitlement to pecuniary compensatory damages in the form of future lost earnings. View "PERLICK v. DVA " on Justia Law

The Chemehuevi Indian Tribe filed a complaint against the United States, alleging mismanagement of funds and breach of trust. The Tribe sought an accounting and damages for the alleged mismanagement of the Parker Dam compensation funds, the Indian Claims Commission (ICC) Judgment funds, and the suspense accounts. The Tribe also claimed that the U.S. government's failure to approve a proposed lease of its water rights constituted a Fifth Amendment taking and a breach of trust.The United States Court of Federal Claims dismissed the Tribe's complaint, ruling that it lacked subject-matter jurisdiction. The court found that the Tribe was essentially seeking an accounting to discover potential claims against the government, rather than asserting a right to be paid a certain sum. The court also dismissed the Tribe's claims related to the proposed water rights lease, stating that the claim was outside the six-year statute of limitations.On appeal, the United States Court of Appeals for the Federal Circuit affirmed the lower court's dismissal of the Tribe's complaint for lack of subject-matter jurisdiction. The appellate court agreed that the Tribe was seeking an accounting to discover potential claims, rather than asserting a right to be paid a certain sum. The court also affirmed the dismissal of the Tribe's claim related to the proposed water rights lease, agreeing that it was outside the statute of limitations. However, the appellate court vacated the lower court's dismissal of the Tribe's claim for failure to state a takings claim, stating that the Tribe's decision to lease the water off-reservation could fulfill the purpose of the reservation. View "CHEMEHUEVI INDIAN TRIBE v. US " on Justia Law

Insulet Corp. and EOFlow are medical device manufacturers that produce insulin pump patches. Insulet began developing its OmniPod product in the early 2000s, and EOFlow started developing its EOPatch product after its founding in 2011. Around the same time, four former Insulet employees joined EOFlow. In 2023, reports surfaced that Medtronic had started a process to acquire EOFlow. Soon after, Insulet sued EOFlow for violations of the Defend Trade Secrets Act (DTSA), seeking a temporary restraining order and a preliminary injunction to enjoin all technical communications between EOFlow and Medtronic in view of its trade secrets claims.The U.S. District Court for the District of Massachusetts temporarily restrained EOFlow from disclosing products or manufacturing technical information related to the EOPatch or OmniPod products. The court then granted Insulet’s request for a preliminary injunction, finding strong evidence that Insulet is likely to succeed on the merits of its trade secrets claim, strong evidence of misappropriation, and that irreparable harm to Insulet crystallized when EOFlow announced an intended acquisition by Medtronic. The injunction enjoined EOFlow from manufacturing, marketing, or selling any product that was designed, developed, or manufactured, in whole or in part, using or relying on alleged trade secrets of Insulet.The United States Court of Appeals for the Federal Circuit reversed the district court’s order. The court found that the district court had failed to address the statute of limitations, lacked a tailored analysis as to what specific information actually constituted a trade secret, and found it hard to tell what subset of that information was likely to have been misappropriated by EOFlow. The court also found that the district court had failed to meaningfully engage with the public interest prong. The court concluded that Insulet had not shown a likelihood of success on the merits and other factors for a preliminary injunction. The case was remanded for further proceedings consistent with the opinion. View "INSULET CORP. v. EOFLOW, CO. LTD. " on Justia Law